VANCOUVER, British Columbia, April 27, 2022 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2021 and provided a corporate update.
2021 Highlights and Recent Developments
Summary Financial Results for the fourth quarter and year ended December 31, 2021
The Company commenced operations on March 25, 2021, concurrent with the closing of the qualifying transaction with Vincero Capital Corp. and began trading on the Toronto Venture Exchange under the symbol RKV on April 1, 2021. At December 31, 2021, the Company had positive working capital of approximately $3.0 million.
For the three and twelve months ending December 31, 2021 the Company reported a net loss of $751,353 and $5,521,139, respectively. Research and development operating expenses were $473,799 and $1,502,439 for the three and twelve months ended December 31, 2021, respectively. General and administrative expenses were $277,907 and $971,891 for the three and twelve months ending December 31, 2021, respectively. Total cash operating expenses related to research and development and general and administrative expenses for the three and twelve months ended December 31, 2021 were $529,293 and 1,691,905, respectively.
Selected Financial Information | As at December 31, 2021 $ |
Cash & cash equivalents | 2,811,541 |
Working capital | 2,956,994 |
Intangible assets | 5.587,269 |
Total Assets | 8,658,242 |
Total liabilities | 113,979 |
Deficit | (5,521,152) |
Total equity | 8,544,263 |
Statements of net loss and comprehensive loss data: | For the three months ended December 31, 2021 $ |
For the year ended December 31, 2021 $ |
|
Research & Development | 473,799 | 1,502,439 | |
General and administrative | 277,907 | 971,891 | |
Net loss and comprehensive loss | (751,353) | (5,521,139) | |
Basic and diluted income (loss) per share | (.01) | (0.10) | |
Operating cash burn | 529,293 | 1,691,905 | |
Weighted average shares outstanding | 69,808,000 | 53,622,734 |
Rakovina Therapeutics’ financial statements as filed with SEDAR can be accessed from the Company’s website at: https://www.rakovinatherapeutics.com/corporate-profile/
About Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com.
Additional Information
The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com.
Contact: | |
Rakovina Therapeutics Inc. David Hyman Chief Financial Officer Email: info@rakovinatherapeutics.com |
Investor Relations Contact IR@rakovinatherapeutics.com Media Contact |
HALIFAX, NS / ACCESSWIRE / July 2, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today…
Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT"…
NEW YORK, July 2, 2024 /PRNewswire/ -- The global load monitoring systems market size is…
ATLANTA, July 2, 2024 /PRNewswire/ -- Aveanna Healthcare ("Aveanna") has learned of a data security…
These 50 rising stars are honored for their trailblazing innovations in shaping global culture UNIONDALE,…
MRO achieves highest client satisfaction ratings for ROI and secure provider data exchange in Black…